Plate Nº 70 · recorded October 14, 2026
Health & Medicine ResearchReported finding
Protein Lets "Zombie Cells" Hide From Immune System, Study Finds
Cedars-Sinai researchers found the protein PD-L2 helps aging "zombie cells" evade the immune system. Blocking it in mice cut inflammation and improved blood sugar and strength.
By Elena Vasquez3 min read683 words
In brief
- The study appeared in Cell Metabolism on October 14, 2026.
- Blocking or removing PD-L2 reduced senescent cell buildup, inflammation, and improved blood sugar and grip strength in mice.
- Senescent human cells produce more PD-L2 than younger cells, and levels rise with age in some human tissues.
- The research was led by Cedars-Sinai Health Sciences University.
- Human safety and benefit studies are still needed before any therapy.
By Elena Vasquez
Blocking a single protein called PD-L2 reduced harmful "zombie cells," cut inflammation, and improved blood sugar control and grip strength in mice, according to a Cedars-Sinai study published October 14, 2026, in the journal Cell Metabolism.
The protein may explain why these damaged, aging cells escape the immune system and pile up in the body as we get older. Researchers say PD-L2 could become both a drug target and a blood marker for tracking the cells.
"Our findings suggest that PD-L2 may help aging cells stay in the body when they would normally be removed by the immune system," said Selim Chaib, PhD, research assistant professor of Medicine at Cedars-Sinai and first and co-corresponding author of the study.
What are "zombie cells"?
Scientists call them senescent cells. They've stopped dividing, but they stay alive, lingering in tissues instead of disappearing. It's an everyday part of aging and damage.
The trouble starts when they accumulate. Senescent cells release substances that trigger inflammation and disrupt nearby healthy cells. That buildup has been linked to a range of health problems that become more common with age.
Normally, the immune system clears these cells out. Why it fails to do so has been an open question. The new work points to PD-L2.
In short: the protein may act as a molecular camouflage that keeps aging cells from being detected and destroyed.
What did the mouse experiments show?
The team ran experiments in lab mice in which PD-L2 was either genetically removed or blocked with antibodies. Both approaches worked.
The results, in brief:
- Reduced accumulation of senescent cells in tissues
- Lower levels of the inflammatory substances those cells release
- Improved ability to process sugar
- Greater grip strength, a measure of physical function affected by aging
The improvements went beyond the cellular level. Mice with reduced PD-L2 activity performed better on functions that typically decline with age.
The researchers didn't stop with mice. They also examined human cells and tissues, and the pattern held: senescent human cells produced more PD-L2 than younger cells, and protein levels rose with age in certain human tissues. That suggests the mechanism seen in mice may also be relevant to human aging — though human relevance remains to be proven directly.
Could this lead to a treatment for age-related disease?
The findings raise the possibility that blocking PD-L2 could help the immune system recognize and eliminate harmful aging cells, potentially easing some health problems tied to their buildup.
"If we can find a way to block this protein, we may be able to help the immune system get rid of these cells and potentially improve health problems linked with aging," said James Kirkland, MD, PhD, director of the Center for Advanced Gerotherapeutics and senior author of the study.
Caution is warranted. The benefits so far come from mice and lab-grown human cells, not from patients. Researchers still need to establish whether blocking PD-L2 is safe in people and whether it delivers meaningful health benefits. They also hope to clarify how the protein contributes to specific age-related diseases.
The bottom line: PD-L2 gives scientists a concrete lead, but any therapy for humans is years and several studies away.
Who did the work?
The study was led by Cedars-Sinai Health Sciences University, with a large collaborating team including researchers Larissa Langhi Prata, Masayoshi Suda, Andres Sola, and dozens of co-authors across multiple institutions.
Funding came primarily from the US National Institutes of Health, along with the Hevolution Foundation, the Connor Fund, the Noaber Foundation, the Glenn Foundation for Medical Research, and others.
Some authors have financial interests related to the research. Chaib holds patents or pending patents on PD-L2, some licensed to Rejuveron Senescence Therapeutics, and several co-authors hold patents covering senolytic drugs — treatments designed to clear senescent cells — or equity in companies in the field.
The takeaway: a newly identified immune-evasion protein offers a promising, still-early path toward clearing zombie cells and, maybe someday, softening age-related disease.
via dx.doi.org (Original)
More from Elena Vasquez
Show full bio
Correspondent covering money, funding and market shifts around general science news at SciBeat.
234 articles